{"id":1827,"date":"2017-06-21T08:43:08","date_gmt":"2017-06-21T08:43:08","guid":{"rendered":"https:\/\/www.despatch.com\/blog\/?p=1827"},"modified":"2019-04-10T15:10:41","modified_gmt":"2019-04-10T15:10:41","slug":"fda-approves-symjepi-a-cheaper-substitute-to-epipen-allergy-shot","status":"publish","type":"post","link":"https:\/\/www.despatch.com\/blog\/fda-approves-symjepi-a-cheaper-substitute-to-epipen-allergy-shot\/","title":{"rendered":"FDA Approves Symjepi, a Cheaper Substitute to EpiPen Allergy Shot"},"content":{"rendered":"<p>Mylan\u2019s EpiPen has long been the most popular and recognizable allergy shot medication.<\/p>\n<p>However, it has been widely criticized for being unaffordable, typically priced at hundreds of dollars.<\/p>\n<p>Now, there is a new, cheaper alternative from manufacturer Adamis Pharmaceuticals Corporation after its Symjepi allergy shot was recently approved by US Food and Drug Administration.<\/p>\n<p><a href=\"https:\/\/apnews.com\/4b8f8a38b8a04783adfb1b9e4b4b7e54\/FDA-approves-new,-cheaper-rival-to-EpiPen-allergy-shot?utm_campaign=SocialFlow&amp;utm_source=Twitter&amp;utm_medium=AP\">According to the A<em>ssociated Press<\/em><\/a>, the drug will be rolled out later this year and will feature\u00a0two, single-dose syringes filled with the hormone epinephrine.<\/p>\n<p>An affordable substitute allergy shot capable of stopping potentially fatal allergy attacks from bug bites to food consumption is a welcome sight.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mylan\u2019s EpiPen has long been the most popular and recognizable allergy shot medication. However, it has been widely criticized for being unaffordable, typically priced at hundreds of dollars. Now, there is a new, cheaper alternative from manufacturer Adamis Pharmaceuticals Corporation after its Symjepi allergy shot was recently approved by US Food and Drug Administration. According [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2839,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[58],"tags":[782],"acf":[],"_links":{"self":[{"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/posts\/1827"}],"collection":[{"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/comments?post=1827"}],"version-history":[{"count":5,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/posts\/1827\/revisions"}],"predecessor-version":[{"id":1833,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/posts\/1827\/revisions\/1833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/media\/2839"}],"wp:attachment":[{"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/media?parent=1827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/categories?post=1827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.despatch.com\/blog\/wp-json\/wp\/v2\/tags?post=1827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}